Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression

Williams–Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment wi...

Full description

Bibliographic Details
Main Authors: Paula Ortiz-Romero, Alejandro González-Simón, Gustavo Egea, Luis A. Pérez-Jurado, Victoria Campuzano
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.670785/full
id doaj-be145bfe15ff483e9bcba89e641ade63
record_format Article
spelling doaj-be145bfe15ff483e9bcba89e641ade632021-08-03T07:34:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-08-011210.3389/fphar.2021.670785670785Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia OverexpressionPaula Ortiz-Romero0Alejandro González-Simón1Gustavo Egea2Gustavo Egea3Luis A. Pérez-Jurado4Luis A. Pérez-Jurado5Luis A. Pérez-Jurado6Victoria Campuzano7Victoria Campuzano8Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi I Sunyer, IDIBAPS-UB, Barcelona, SpainUnitat de Genètica, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, SpainCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, SpainServei de Genètica, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, SpainWilliams–Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment with curcumin, verapamil, and a combination of both. These compounds have been proven to have beneficial effects over different cognitive aspects of various murine models and, thus, may have neuroprotective effects in WBS. Treatment was administered orally dissolved in drinking water. A set of behavioral tests demonstrated the efficiency of combinatorial treatment. Some histological and molecular analyses were performed to analyze the effects of treatment and its underlying mechanism. CD mice showed an increased density of activated microglia in the motor cortex and CA1 hippocampal region, which was prevented by co-treatment. Behavioral improvement correlated with the molecular recovery of several affected pathways regarding MAPK signaling, in tight relation to the control of synaptic transmission, and inflammation. Therefore, the results show that co-treatment prevented behavioral deficits by recovering altered gene expression in the cortex of CD mice and reducing activated microglia. These findings unravel the mechanisms underlying the beneficial effects of this novel treatment on behavioral deficits observed in CD mice and suggest that the combination of curcumin and verapamil could be a potential candidate to treat the cognitive impairments in WBS patients.https://www.frontiersin.org/articles/10.3389/fphar.2021.670785/fullWilliams–Beuren syndromecurcuminverapamilmiceactivated gliabehavior
collection DOAJ
language English
format Article
sources DOAJ
author Paula Ortiz-Romero
Alejandro González-Simón
Gustavo Egea
Gustavo Egea
Luis A. Pérez-Jurado
Luis A. Pérez-Jurado
Luis A. Pérez-Jurado
Victoria Campuzano
Victoria Campuzano
spellingShingle Paula Ortiz-Romero
Alejandro González-Simón
Gustavo Egea
Gustavo Egea
Luis A. Pérez-Jurado
Luis A. Pérez-Jurado
Luis A. Pérez-Jurado
Victoria Campuzano
Victoria Campuzano
Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
Frontiers in Pharmacology
Williams–Beuren syndrome
curcumin
verapamil
mice
activated glia
behavior
author_facet Paula Ortiz-Romero
Alejandro González-Simón
Gustavo Egea
Gustavo Egea
Luis A. Pérez-Jurado
Luis A. Pérez-Jurado
Luis A. Pérez-Jurado
Victoria Campuzano
Victoria Campuzano
author_sort Paula Ortiz-Romero
title Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
title_short Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
title_full Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
title_fullStr Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
title_full_unstemmed Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
title_sort co-treatment with verapamil and curcumin attenuates the behavioral alterations observed in williams–beuren syndrome mice by regulation of mapk pathway and microglia overexpression
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-08-01
description Williams–Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment with curcumin, verapamil, and a combination of both. These compounds have been proven to have beneficial effects over different cognitive aspects of various murine models and, thus, may have neuroprotective effects in WBS. Treatment was administered orally dissolved in drinking water. A set of behavioral tests demonstrated the efficiency of combinatorial treatment. Some histological and molecular analyses were performed to analyze the effects of treatment and its underlying mechanism. CD mice showed an increased density of activated microglia in the motor cortex and CA1 hippocampal region, which was prevented by co-treatment. Behavioral improvement correlated with the molecular recovery of several affected pathways regarding MAPK signaling, in tight relation to the control of synaptic transmission, and inflammation. Therefore, the results show that co-treatment prevented behavioral deficits by recovering altered gene expression in the cortex of CD mice and reducing activated microglia. These findings unravel the mechanisms underlying the beneficial effects of this novel treatment on behavioral deficits observed in CD mice and suggest that the combination of curcumin and verapamil could be a potential candidate to treat the cognitive impairments in WBS patients.
topic Williams–Beuren syndrome
curcumin
verapamil
mice
activated glia
behavior
url https://www.frontiersin.org/articles/10.3389/fphar.2021.670785/full
work_keys_str_mv AT paulaortizromero cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT alejandrogonzalezsimon cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT gustavoegea cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT gustavoegea cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT luisaperezjurado cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT luisaperezjurado cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT luisaperezjurado cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT victoriacampuzano cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
AT victoriacampuzano cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression
_version_ 1721223610903822336